Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche’s Actemra Gets Advisory Committee Review

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Arthritis Drugs Advisory Committee evaluates the interleukin-6 receptor inhibitor for rheumatoid arthritis July 29.

You may also be interested in...



Roche’s Actemra Gets FDA Panel Vote Of Confidence With Robust P-vigilance

Arthritis Drugs Advisory Committee selects more cautious starting dose for Roche’s rheumatoid arthritis therapy during July 29 meeting.

Roche’s Actemra Gets FDA Panel Vote Of Confidence With Robust P-vigilance

Arthritis Drugs Advisory Committee selects more cautious starting dose for Roche’s rheumatoid arthritis therapy during July 29 meeting.

FDA Calls Roche’s Arthritis Drug Actemra Effective Ahead Of Panel Meeting

First-in-class interleukin-6 receptor inhibitor may sidestep safety concerns seen with anti-TNFs.

Related Content

Topics

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel